GW906 clinical trials
GW906 is named as an intervention in 3 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Shenzhen Salubris Pharmaceuticals Co., Ltd. The most-studied condition is Hypertension.
Patient leaflets for GW906
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of GW906
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
An Extension Trial of GW 906 in Participants With Essential Hypertension
NCT07879755 · ClinicalTrials.gov ↗ · Hypertension
|
Not applicable | Recruiting | Shenzhen Salubris Pharmaceuticals Co., Ltd | China |
|
A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications
NCT07835984 · ClinicalTrials.gov ↗ · Hypertension
|
Phase 2 | Not yet open | Shenzhen Salubris Pharmaceuticals Co., Ltd | China |
|
A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension
NCT07835971 · ClinicalTrials.gov ↗ · Hypertension
|
Phase 2 | Active, closed | Shenzhen Salubris Pharmaceuticals Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with GW906
1 conditionSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Shenzhen Salubris Pharmaceuticals Co., Ltd | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about GW906 trials
How many clinical trials are testing GW906?
3 current trials in our China register name GW906 as a drug or biological intervention, as of the registry sync on 22 November 2026. Completed and withdrawn studies are not counted.
Are GW906 trials recruiting patients?
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors GW906 clinical trials?
The lead sponsor is Shenzhen Salubris Pharmaceuticals Co., Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how GW906 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how GW906 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists GW906 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.